QA: Neubase Therapeutics Inc in us_pharma/2020

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001173281_2021_Neubase_Therapeutics_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}
warning Missing logo subcommand.report {}
warning Large missing amount for aggregate "Liabilities" added to remainder. industry.us_generic {'missing_ratio': inf, 'aggregate_val': 3149633, 'exp_sum': 0, 'exp_to_value': {'LiabilitiesCurrent': 0, 'LiabilitiesNoncurrent': 0, 'remainder_Liabilities': 0}}

Graph

Absolute values for 0001173281, Neubase Therapeutics Inc

  xvar xval
0 AssetsCurrent 32,808,540
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 1,166,934
3 remainder_Assets 468,807
4 LiabilitiesCurrent 0
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 3,149,633
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 10,123,298
9 ResearchAndDevelopmentExpense 6,946,008
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome -315,214
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 34,444,281
1 Liabilities 3,149,633
2 Expenses 17,069,306
3 Revenues 0
4 StockholdersEquity 31,294,648
5 NetIncome -17,384,520
6 ComprehensiveNetIncome -17,384,520
7 BaseVar 27,489,217
8 EconomicCapitalRatiobeforeLimitedLiability 2.70
9 EconomicCapitalRatio 3.49

Edgar->Model Mapping

Feature Distribution

Change over Time